IRIS
BERTINO, Gaetano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.874
EU - Europa 3.470
AS - Asia 2.984
SA - Sud America 709
AF - Africa 405
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 7
Totale 14.461
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.562
SG - Singapore 1.508
CN - Cina 1.075
IT - Italia 1.003
IE - Irlanda 867
UA - Ucraina 780
BR - Brasile 658
CA - Canada 279
CI - Costa d'Avorio 267
RU - Federazione Russa 226
DE - Germania 119
SE - Svezia 109
GB - Regno Unito 93
SN - Senegal 78
IN - India 75
KR - Corea 70
VN - Vietnam 69
FR - Francia 45
FI - Finlandia 38
NL - Olanda 34
BE - Belgio 26
UZ - Uzbekistan 26
BD - Bangladesh 25
TR - Turchia 25
AT - Austria 24
PL - Polonia 23
CZ - Repubblica Ceca 21
CH - Svizzera 18
MX - Messico 17
AR - Argentina 16
HK - Hong Kong 16
MA - Marocco 15
ZA - Sudafrica 15
GR - Grecia 14
IQ - Iraq 13
EU - Europa 10
IR - Iran 10
NG - Nigeria 10
JP - Giappone 9
EC - Ecuador 8
PK - Pakistan 8
SA - Arabia Saudita 8
QA - Qatar 7
AU - Australia 6
CO - Colombia 6
ES - Italia 6
IL - Israele 6
KE - Kenya 6
LB - Libano 6
NP - Nepal 6
BG - Bulgaria 5
LT - Lituania 5
PY - Paraguay 5
UY - Uruguay 5
VE - Venezuela 5
JM - Giamaica 4
JO - Giordania 4
KZ - Kazakistan 4
PA - Panama 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
HN - Honduras 3
HR - Croazia 3
RO - Romania 3
ET - Etiopia 2
GA - Gabon 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GP - Guadalupe 1
HU - Ungheria 1
ID - Indonesia 1
IM - Isola di Man 1
KG - Kirghizistan 1
LK - Sri Lanka 1
NA - Namibia 1
NZ - Nuova Zelanda 1
TT - Trinidad e Tobago 1
UG - Uganda 1
VI - Stati Uniti Isole Vergini 1
Totale 14.461
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.126
Singapore 928
Dublin 863
Chandler 747
Jacksonville 691
Chicago 395
Boardman 349
Abidjan 267
Nanjing 248
Lawrence 241
Andover 239
Cambridge 238
Toronto 220
Catania 189
Los Angeles 184
Dallas 157
Hefei 156
Ashburn 152
Beijing 138
Houston 138
Des Moines 125
Wilmington 99
San Mateo 98
Civitanova Marche 97
Dakar 78
Shenyang 75
Seoul 70
Nanchang 69
Saint Petersburg 65
Council Bluffs 61
São Paulo 55
Hebei 54
Milan 52
Changsha 50
Ottawa 46
Bremen 45
The Dalles 45
Tianjin 43
Jiaxing 42
Mountain View 41
Columbus 38
Palermo 33
Dong Ket 29
Brooklyn 27
Munich 27
Rome 27
Brussels 26
Kochi 25
Moscow 24
Mascalucia 23
New York 22
Belo Horizonte 21
Turku 21
Hong Kong 16
Norwalk 16
Rio de Janeiro 16
Falls Church 15
Mumbai 15
Warsaw 15
Hanoi 14
London 14
Naples 14
Redmond 14
Amsterdam 12
Brasília 12
Brno 12
Foggia 12
Jinan 12
Leawood 12
Pune 12
Seattle 12
Washington 12
Boston 11
Kunming 11
Modica 11
San Francisco 11
Tashkent 11
Abuja 10
Den Haag 10
Guangzhou 10
Johannesburg 10
Liberty Lake 10
Turin 10
Atlanta 9
Chennai 9
Florence 9
Helsinki 9
Ho Chi Minh City 9
Phoenix 9
Porto Alegre 9
Tokyo 9
Charlotte 8
Dhaka 8
Gravina di Catania 8
Hangzhou 8
Ningbo 8
Zhengzhou 8
Baghdad 7
Frankfurt Am Main 7
Istanbul 7
Totale 9.832
Salva come PNG Salva come JPEG
Nome #
Carbohydrate 19.9 Antigen Serum Levels in Liver Disease 144
Commentary on "Insertion of Totally Implantable Central Venous Access Devices by Surgeons" - What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications? 144
Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research 128
Correction to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research (Internal and Emergency Medicine, (2022), 17, 3, (887-909), 10.1007/s11739-022-02967-1) 119
Eterozigosi H36D per Emocromatosi in pazienti affetti da Steatoepatite e Epatite cronica da virus C 117
D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis 114
Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives 113
Anorectal mucosal melanoma 111
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine 111
Critical appraisal of the European Union Scientific Committee on Health, Environmental, and Emergency Risks (SCHEER) Preliminary Opinion on electronic cigarettes 110
A study about mechanism of des-gamma-carboxy prothrombin’s production in hepatocellular carcinoma 108
Carotid Intima-Media Thickness and Liver Histology in Hemodialysis Patients with Non-Alcoholic Fatty Liver Disease 107
Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer 107
Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study 107
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 105
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. 102
Obesity and related diseases: an epidemiologic study in Eastern Sicily 101
Type II Mixed Cryoglobulinemia In Patients With Hepatitis C Virus: Treatment with Pegylated-Interferon and Ribavirin 101
Possibile associazione di anemia normocromica con maggiore incremento delle molecole di adesione ICAM-2 e VCAM-1 in pazienti con cirrosi epatica: studio pilota 100
Hepatocellular carcinoma serum markers 97
High carbohydrate 19-9 antigen serum levels in patients with nonmelanoma skin cancer and primary occult cancer 94
Eritropoietina nel trattamento dell'anemia secondaria a terapia con interferone peghilato e ribavirina 93
Assessing degree of hepatic fibrosis in patients with chronic liver disease using gadoxetic acid-enhanced liver MRI: Preliminary results 93
Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis 92
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study 91
Circulating adhesion molecules in patients with virus-related chronic diseases of the liver 90
Laparoscopic Reversal of Hartmann's Procedure: State of the Art 20 Years after the First Reported Case 89
Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase -2 in patients with HCV-related chronic hepatitis. Relationship to histological features 89
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 88
Acetyl-L-carnitine can slow the progression from prefrailty to frailty in older subjects. A randomized interventional clinical trial 87
Evaluation of health status in patients with hepatitis c treated with and without interferon 87
Rosuvastatin reduces non alcoholic fatty liver diseasa in patients with chronic hepatitis C treated with alpha-interferon and ribavirin 87
Folate levels in hepatocellular carcinoma patients with portal vein thrombosis 87
Homocysteine serum levels as prognostic marker of hepatocellular carcinoma with portal vein thrombosis 86
Trattamento con peg-interferone e ribavirina nell’epatite cronica attiva C ed insorgenza di malattia celiaca: esiste una relazione ? 85
Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature 85
Giant cavernous liver hemangiomas: is it the time to change the size categories? 83
Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic epatiti C treated with pegylated interferon α and ribavirin 82
Carnitine Serum Levels in Frail Older Subjects 82
Epatite cronica: un caso di sovrapposizione epatite autoimmune-epatite virale 81
A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 79
Systemic Therapies in Hepatocellular carcinoma: present and future 79
Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions 79
Resveratrol in Patients with Minimal Hepatic Encephalopathy 79
Trattamento dell'epatite cronica B, HBeAg negativa, con terapia di combinazione: Adefovir e Interferone-Pegilato alfa 2a vs Adefovir (Studio PAC: Peg Adefovir Combination) 78
A therapeutic education and medical support program improves adherence to therapy with peg-interferon plus ribavirin therapy and increases sustained virological response in patients with chronic hepatitis C 78
Riduzione della densità minerale ossea volumetrica (pQCT) in pazienti con epatopatia cronica HCV-correlata: confronto con la misurazione DEXA 77
Rare benign tumors of the liver: still rare? 77
Clinical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electric cigarettes 76
Incidence and causes of neonatal hyperbilirubinemia in a center of Catania 76
Circulating erytropoietin in microalbuminuric type 2 diabetic patients with normal renal function: a pilot study 76
ON-TREATMENT HBsAg DECLINE IS ASSOCIATED WITH SUBSEQUENT HBsAg REDUCTION IN HBeAg NEGATIVE CHRONIC HEPATITIS B 76
Association Between Diabetes Mellitus, Hepatic Steatosis And Fibrosis In Chronic Hepatitis C Patients 76
A case of Overlap Syndrome:Autoimmune idiopatic hepatitis/pulmonary idiopatic hypertension 76
Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study 76
Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis 76
Biochemical long-term outcomes in chronic hepatitis C patients treated with a twelve months course of alpha lymphoblastoid interferon 75
An unusual case of HBV reactivation in a patient with cholangitis and choledocho-lithiasis undergone to ERCP. A case report 75
A phase IIIb, 2X2 factorial, double blind study of 48 versus 96 weeks of peg-Interferon alpha 2a 180 micrg, with or without 24 weeks of Entecavir in adult patients with HbeAg negative chronic hepatitis B 74
Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype 74
AIDS. Sindrome da Immunodeficienza Acquisita 73
Totally Implantable Venous Access Devices: Efforts Are Needed to Standardize Procedures to Avoid Complications 73
Hepatocellular Carcinoma: present and future 73
Chronic anaemia and adhesion molecules in patients with liver cirrhosis. A preliminary report 72
Vaccinazione anti-epatite B: differenze della risposta immune con Hevac B Pasteur in rapporto all'età 72
Carbohydrate 19-9 antigen in chronic viral hepatitis without neoplasia is associated with the severity of liver disease 72
Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection 71
Chronic hepatitis C: This and the new era of treatment 71
Combined duodenal and pancreatic major trauma in high risk patients: can a partial reconstruction be safe? 71
Endozepine-4 levels are increased in hepatic coma. 71
Hepatocellular carcinoma and the risk of occupational exposure. 70
Silybin supplementation during HCV therapy with pegylated interferon-a plus ribavirin reduces depression and anxiety and increases work ability 70
Reduction of volumetric bone mineral density in postmenopausal women with HCV-correlated chronic liver disease: a peripheral quantitative computed tomogtraphy (pQCT) study 70
Current practice of chronic hepatitis B treatment in Southern Italy 70
Eritropoietina nel trattamento dell’anemia secondaria a terapia con interferone peghilato e ribavirina 69
Hepatocellular Carcinoma 69
Potential role of probiotics on colorectal cancer prevention 69
Priority of the chronic HBV pathology in a samples of subjects suffering from liver disorder and hospitalized in the last triennium 68
INFEZIONE DA HAV IN PAZIENTI CON EPATITE CRONICA HCV-CORRELATA 68
POST-LOAD INSULIN RESISTANCE IS AN INDEPENDENT PREDICTOR OF HEPATIC FIBROSIS IN DIABETIC PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE 68
A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin 68
ON-TREATMENT SERUM HBsAG DECLINE DURING TELBIVUDINE THERAPY IN NAÏVE CHRONIC HEPATITIS B: CASE REPORT 67
Does follow-up offer the best quality of life for patients affected by so-called 'giant' haemangiomas of the liver? 67
Telbivudine on-treatment HBsAg loss in naïve HBeAg negative chronic hepatitis B: A case report and brief review of the literature 67
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis 67
Iron depletion and lifestyle modifications improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia 66
Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study 66
Experience with vaccination against hepatitis B 65
Behavior of alpha-1-antitrypsin in adults with chronic liver disease 65
La metalloproteinasi-2 è un marker indiretto di citonecrosi e fibrosi epatica nell’epatite cronica HCV-correlata 65
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. 65
What are the true advantages of devices for hepatic parenchimal transection in open surgery? 64
Digestive diseases. 2022-2025 edition 63
Polyunsaturated phosphatidylcholine (EPL) in the management of liver steatosis 63
The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases 63
Plasma ICAM-1 and VCAM-1 levels in type 2 diabetic patients with and without microalbuminuria 63
Pegylated-interferon and ribavirin therapy of HCV-related type II mixed cryoglobulinemia 63
Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases 62
Ferro e ferrodeplezione nell'epatite cronica HCV-correlata 62
Some patients with HCC havent't abnormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels 62
Totale 8.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.892
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.236 0 0 169 40 377 49 159 18 102 60 183 79
2021/20221.735 222 279 20 27 267 14 255 55 137 6 62 391
2022/20232.609 257 97 40 229 241 442 17 449 673 25 79 60
2023/20241.222 69 162 45 56 49 264 24 91 13 41 230 178
2024/20254.856 77 754 306 226 1.002 549 150 190 343 539 346 374
2025/20261.215 611 556 48 0 0 0 0 0 0 0 0 0
Totale 15.066